Sanofi Pasteur, the vaccines division of Sanofi, announced that the FDA has approved the supplemental biologics license application (sBLA) of Fluzone Quadrivalent vaccine, an inactivated four-strain influenza virus vaccine for intramuscular injection.

Fluzone Quadrivalent is the first four-strain vaccine approved for use in patients as young as 6 months. The vaccine includes two A strains and two B strains to help protect against influenza and is preservative-free. Fluzone Quadrivalent is the latest addition to the Fluzone family of vaccines that include Fluzone, Fluzone Intradermal, and Fluzone High-Dose–all of which are trivalent vaccines.

The Fluzone Quadrivalent vaccine will be available for the 2013–2014 influenza season. It will be supplied as 0.25mL and 0.5mL prefilled syringes in 10-count packages and 0.5mL single-dose vials in 10-count packages. Healthcare providers may reserve vaccines by visiting

For more information call (800) VACCINE or visit